Teva challenges key US patents for Atripla
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has informed Gilead Sciences that it has submitted an ANDA with a paragraph IV challenge, and is seeking to market a generic version of the once-daily triple combination product for HIV/AIDS, Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate). The product is sold through a joint venture between Gilead and Bristol-Myers Squibb.